Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer

Front Oncol. 2021 Nov 24:11:752689. doi: 10.3389/fonc.2021.752689. eCollection 2021.

Mai F Tolba^{1

2}, Cesar A Santa-Maria³, Adriana Albini⁴, Emile R Chimusa⁵, Basel K Al-Ramadi^{6

7}, Sara M Tolaney^{8

9}

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
² School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation (GAF), New Administrative Capital, Cairo, Egypt.
³ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, United States.
⁴ Laboratory of Vascular Biology and Angiogenesis, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
⁵ Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa.
⁶ Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
⁷ Zayed Center for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
⁹ Department of Medicine, Harvard Medical School, Boston, MA, United States.

No abstract available

Keywords: biomarker; breast cancer; combination therapy; immune checkpoint inhibitors; immunotherapy.

Publication types